US20150283112A1 - Composition comprising myricetin as active ingredient for enhancing exercise performance or fatigue recovery - Google Patents

Composition comprising myricetin as active ingredient for enhancing exercise performance or fatigue recovery Download PDF

Info

Publication number
US20150283112A1
US20150283112A1 US14/435,424 US201314435424A US2015283112A1 US 20150283112 A1 US20150283112 A1 US 20150283112A1 US 201314435424 A US201314435424 A US 201314435424A US 2015283112 A1 US2015283112 A1 US 2015283112A1
Authority
US
United States
Prior art keywords
myricetin
composition
mouse
canceled
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/435,424
Other languages
English (en)
Inventor
Kyong-Tai Kim
Bo-Hwa Choi
Hoe-Yune Jung
Jae-Cheon Shin
Sang-Taek Oh
Myung-Su Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOKOGEN Co Ltd
Original Assignee
Academy Industry Foundation of POSTECH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academy Industry Foundation of POSTECH filed Critical Academy Industry Foundation of POSTECH
Assigned to POSTECH ACADEMY-INDUSTRY FOUNDATION reassignment POSTECH ACADEMY-INDUSTRY FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOI, BO-HWA, KANG, Myung-Su, KIM, KYONG-TAI, OH, SANG-TAEK, SHIN, Jae-Cheon, JUNG, Hoe-Yune
Publication of US20150283112A1 publication Critical patent/US20150283112A1/en
Assigned to BIOKOGEN CO., LTD. reassignment BIOKOGEN CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: POSTECH ACADEMY-INDUSTRY FOUNDATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A23L1/3002—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient to enhance exercise capacity or recover from fatigue.
  • a flavonol derivative, myricetin is a main ingredient of the bark of Chinese bayberry, which is used as oriental medicine, and used as a drug for stomatitis, diuretic, a depressant, etc. It is known that myricetin is also included in clover seeds, leaves of Lysimachia christinae , Korean rhododendron , and succedanea, other than Chinese bayberry. It has been reported that myricetin has various effects on treating cancer, preventing and treating Alzheimer's disease, preventing inflammation, and preventing and treating diabetes. In the Republic of Korea, patents relating to various uses of myricetin are registered. For example, a pharmaceutical composition for preventing or treating liver cancer (Korean Patent No.
  • the present invention is directed to providing a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient to enhance exercise capacity or recover from fatigue.
  • the present invention is also directed to providing a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient to prevent aging and obesity.
  • One aspect of the present invention provides pharmaceutical and food compositions containing myricetin or a pharmaceutically available salt thereof as an active ingredient to enhance exercise capacity or recover from fatigue.
  • Another aspect of the present invention provides pharmaceutical and food compositions containing myricetin or a pharmaceutically available salt thereof as an active ingredient to prevent obesity.
  • composition may be administered into an individual.
  • the “individual” used herein means a target having a disease to be treated, and includes, particularly, humans, or non-human mammals such as primates, mice, rats, dogs, cats, horses and cattle.
  • the pharmaceutical composition of the present invention may include at least one pharmaceutically available carrier, in addition to the above-described active ingredient, and may be prepared in various dosage forms for administration.
  • the pharmaceutical composition of the present invention may be applied through oral or parenteral administration (e.g., intravenous, subcutaneous, abdominal or local administration) according to a desired method, and a dosage may vary depending on a patient's body weight, age, sex, health condition, diet, duration, administration method, excretion rate, or severity of a disease.
  • oral or parenteral administration e.g., intravenous, subcutaneous, abdominal or local administration
  • a dosage may vary depending on a patient's body weight, age, sex, health condition, diet, duration, administration method, excretion rate, or severity of a disease.
  • An exemplary dosage of the pharmaceutical composition of the present invention may vary depending on a condition and body weight of a patient, severity of a disease, a drug type, an administration route or duration, but may be suitably selected by those of ordinary skill in the art.
  • the pharmaceutical composition of the present invention is preferably administered at 0.001 to 100 mg/kg of body weight, and more preferably, at 0.01 to 30 mg/kg of body weight per day. The administration may be performed once or several times a day.
  • the food composition of the present invention may be added to health functional food to enhance exercise capacity or recovery from fatigue.
  • myricetin or a pharmaceutically available salt thereof may be added alone or in combination with other food or a food additive such as glucose, fructose, sucrose, maltose, sorbitol, stevioside, rubsoside, corn syrup, lactose, citric acid, tartaric acid, maltic acid, succinic acid, lactic acid, L-ascorbic acid, d1- ⁇ -tocopherol, sodium erythorbate, glycerin, propyleneglycol, glycerin fatty ester, poly gylcerin fatty ester, sucrose fatty ester, sorbitan fatty ester, gum arabic, carrageenan, casein, gelatin, pectine, agar, vitamin B group, nicotinamide, calcium pantothenate, amino acid, calcium salt, pigment, flavor or a
  • a mixing amount of the active ingredient may be suitably determined according to a purpose of use (prevention, health or therapeutic treatment).
  • myricetin or pharmaceutically available salt thereof of the present invention may be added at 15 wt % or less, and preferably, 10 wt % or less with respect to the source material.
  • the amount may be lower than the above range, and since there is no problem in safety, the active ingredient may be used more than the above range.
  • the food may include a dairy product, soup, a beverage, tea, a drink, an alcoholic beverage, a vitamin complex, and health functional food in its usual acceptation.
  • the composition increases exercise endurance, strengthens strength, enhances a sense of balance, and increases exercise adaptation.
  • the myricetin increases the oxidative metabolism in mitochondria by increasing the expression of a PGC-1 ⁇ , NRF-1 or PPAR- ⁇ gene.
  • Still another aspect of the present invention provides pharmaceutical and food compositions containing myricetin or a pharmaceutically available salt thereof as an active ingredient to recover from fatigue or prevent aging.
  • the recovery of fatigue or the prevention of aging may be enhanced by increasing the expression of SIRT-1 gene.
  • the myricetin of the present invention may be extracted from a source material such as a bark of Chinese bayberry, clover seeds, leaves of lysimachia christinae , Korean rhododendron , succedanea or walnut, and purified myricetin may be purchased in the market.
  • a source of the myricetin is not limited thereto.
  • composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient enhances exercise capacity and strengthens physical strength. In addition, the composition enhances the prevention of aging and recovery from fatigue.
  • the composition of the present invention improves the function of mitochondria to increase energy efficiency and energy consumption, and also has an antiobesity effect.
  • FIG. 1 is a graph showing the enhancement in endurable exercise capacity due to myricetin intake.
  • FIGS. 2A and 2B are graphs showing the strengthening of grip strength of a mouse due to myricetin intake.
  • FIG. 3 is a graph showing the enhancement in sensorimotor function of a mouse duet to myricetin intake.
  • FIGS. 4A-4D show the effects of myricetin on a mouse C2C12 myotubes:
  • FIG. 4A is a graph showing the expression level of a PGC-1 ⁇ gene in the mouse C2C12 myotubes due to myricetin
  • FIG. 4B is a graph showing an expression level of an NRF-1 gene in the mouse C2C12 myotubes due to myricetin
  • FIG. 4C is a graph showing an expression level of a PPAR- ⁇ gene in the mouse C2C12 myotubes due to myricetin
  • FIG. 4D is a graph showing an expression level of a SIRT-1 gene in the mouse C2C12 myotubes due to myricetin.
  • FIGS. 5A and 5B are graphs showing the effects of myricetin on a body weight and appetite of an SD rat when myricetin is administered:
  • FIG. 5A is a graph showing an effect of myricetin on reduction of a body weight, and
  • FIG. 5B is a graph showing an effect of myricetin on a change in food intake.
  • the IUAPC name of a compound of the present invention is 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone, and a structure of the compound is as follows.
  • the myricetin may be isolated from Chinese Bayberry, clover seeds, leaves of lysimachia christinae , Korean rhododendron , or succedanea, but herein, was purchased from Sigma-Aldrich Co.
  • Examples 1 to 4 effects of the myricetin were observed after the myricetin was administered into mice.
  • Example 1 effects of the myricetin on strengthening physical strength and enhancing endurance were examined, and in Example 2, the maximum power of a muscle was measured.
  • Example 3 a sensorimotor function was measured, and in Example 4, the expression of genes involved in the mitochondrial biogenesis and functions, exercise capacity and an antiaging activity were measured.
  • Example 5 an antiobesity effect of the myricetin was measured. Throughout Examples 1 to 5, the effects and use of the myricetin were determined.
  • mice Ten 8-week-old ICR mice were purchased from KOATECH, adapted for 1 week, and then divided into two groups, each group having five mice.
  • the first group was set up as a negative control by administering phosphate buffered saline, and to the second group, myricetin was orally administered daily at a concentration of 50 mg/kg for two weeks.
  • An exercise performance protocol was configured to make the mice run until exhaustion at 25 cm/sec for 20 minutes, 30 cm/sec for 20 minutes, 33 cm/sec for 20 minutes, 36 cm/sec for 20 minutes and 36 cm/sec for 15 minutes with a gradient of 5°, and 30 cm/sec for 15 minutes and 41 cm/sec with a gradient of 10°.
  • mice To adapt the mice to running on the treadmill, the day before the experiment, they were run at 27 cm/sec for 10 minutes with a gradient of 5°.
  • mice were not fed for two hours before the running on the treadmill on the day of the experiment, and then the maximum exercise capacity of the experimental animals was measured after the running on the treadmill.
  • the time to determine the maximum exercise capacity was defined as the time at which the experimental animals were behind 20 seconds or more the speed of the treadmill, or a cumulative number of electric shocks approached 100 times within 5 minutes.
  • a significance of the experiment result was verified by performing a t-test for the test group and the control group, and the results showed a statistically significant difference (***p ⁇ 0.0005).
  • mice To measure an effect of myricetin on enhancing endurance exercise capacity of a mouse, ten 8-week-old ICR-series mice having a body weight of 30 ⁇ 5 g were used. As described in Example 1, the experimental animals were divided into two groups. The first group was determined as a negative control, and to the second group, myricetin was orally administered daily at a concentration of 50 mg/kg for two weeks.
  • FIGS. 2A and 2B it was noted that the maximum muscle strength of the myricetin-administered animal was increased. Accordingly, it was determined that the myricetin intake contributes greatly to enhance muscular strength.
  • mice 8-week-old ICR mice were purchased from KOATECH, adapted for 1 week, and divided into two groups, each group having 5 mice. As described in Example 1, the experimental animals were divided into two groups, and then the first group was determined as a negative control, and to the second group, myricetin was orally administered daily at a concentration of 50 mg/kg using a 1 ml syringe for 2 weeks.
  • a rotarod test (Panlab&Harvard, Spain) was performed on the mice in the control group and the myricetin-administered group.
  • the rotarod test was performed to measure motor coordination (exercise adaptation) and a sense of balance of the animal (Michel Pratte et al., Behavioural brain research 216:313-320, 2011; Medina R. et al., FEBS Lett. 180(1): 77-80, 1985).
  • the tail of the mouse was held by hand and the mouse was put on a rotarod.
  • the speed of the rotarod was increased from 4 to 40 rpm within 5 minutes by an increase of 4 rpm at 30-second intervals.
  • the time during which the mouse stayed on the rotarod was measured.
  • the experiment was repeated five times, and the time during which the mouse stayed the longest on the rotarod was used as a result value.
  • a significance of the experiment result was verified by performing a t-test on each of the test group and the control group, and the result showed a statistically significant difference (**p ⁇ 0.005).
  • Peroxisome proliferator-activated receptor ⁇ coactivator-1 ⁇ (PGC-1 ⁇ ) and nuclear respiratory factor-1 (NRF-1) genes are representative genes involved in the transcription regulating the mitochondrial biogenesis and functions, and known to regulate the function and oxidative metabolism of mitochondria when activated (Christoph Handschin et al., Endocrine Reviews, 27:728-735, 2006). Accordingly, when expression levels of the PGC-1 ⁇ and NRF-1 genes were measured, the enhancement in the mitochondrial biogenesis and functions can be measured. Therefore, in the experimental example, when myricetin was used as a treatment, the expression levels of the PGC-1 ⁇ and NRF-1 genes in the mouse C2C12 myotubes were observed.
  • a peroxisome proliferator-activated receptor- ⁇ (PPAR- ⁇ ) gene is well known as a target for enhancing exercise capacity even when a mouse did not exercise (Vihang A. Narkar et al., Cell, 134:405-415, 2008). Accordingly, when an expression level of the PPAR- ⁇ gene was measured, the possibility to be used as an ergogenic aid may be estimated. Therefore, in this example, when myricetin was treated, the expression level of the PPAR- ⁇ gene in the mouse C2C12 myotubes was observed.
  • SIRT-1 silent mating type information regulation-2 homolog 1
  • SIRT-1 silent mating type information regulation-2 homolog 1
  • the improvement in the function of the mitochondria means that the energy consumption and energy efficiency are increased, and thus the antiobesity effect may be achieved. Accordingly, when the expression levels of the PGC-1 ⁇ , NRF-1, PPAR- ⁇ , SIRT-1 are measured, the antiobesity effect may be estimated.
  • Mouse myoblasts were purchased from the Korean Cell Line Bank (KCLB), and base sequences of primers for ⁇ -actin, SIRT-1, PGC-1 ⁇ , NRF-1 and PPAR- ⁇ genes were as follows:
  • ⁇ -actin (SEQ. ID. NO: 1) forward: GGG AAG GTG ACA GCA TTG (SEQ. ID. NO: 2) reverse: ATG AAG TAT TAA GGC GGA AGA TT SIRT-1 (SEQ. ID. NO: 3) forward: GTT AGC CTT GTA TTA TGG AGA TGA (SEQ. ID. NO: 4) reverse: TGA GGT AAC TGT TTG AAA PGC-1 ⁇ (SEQ. ID. NO: 5) forward: AAG GAC TCT GAG AAC ACT TG (SEQ. ID. NO: 6) reverse: CAA CTG ACC CAA ACA CTT TAC NRF-1 (SEQ. ID. ID.
  • C 2 C 12 1 ⁇ 10 7 C 2 C 12 differentiated into myotubes using 2% horse serum made from the root canal.
  • the mouse C2C12 myotubes were treated with myricetin in different concentrations and cultured for 16 hours, RNA was extracted from the myotubes using TRizol, and then cDNA was synthesized through reverse transcription PCR (RT-PCR).
  • Real time PCR was performed using ⁇ -actin as a control and the primers for respective genes (95° C. for 3 minutes, ⁇ 95° C. for 10 seconds, 60° C. for 10 seconds, 72° C. for 30 seconds > ⁇ 39 cycles, 95° C. for 10 seconds, 65° C. for 5 seconds).
  • the PGC-1 ⁇ , NRF-1, PPAR- ⁇ , and SIRT-1 were corrected with the ⁇ -actin, and the resulting value was obtained.
  • the experiment result was comparatively assayed on the test group and the control group through one way ANOVA, the significance was verified by performing the Turkey's multiples comparison test (Turkey method) as post-testing, and the result showed a statistically significant difference (*p ⁇ 0.05, **p ⁇ 0.005).
  • the treatment with myricetin of the present invention increases the expression of the PGC-1 ⁇ and NRF1 genes regulating the mitochondrial biogenesis and functions, and activates a target for enhancing exercise capacity, PPAR- ⁇ , and an antiaging-related gene, the SIRT-1 gene. Accordingly, it was determined that the myricetin enhances the function of the energy producing organ in cells, the mitochondria, to achieve a physical strength enhancing effect.
  • mice to which myricetin was administered lost weight, and to confirm the weight loss, an additional experiment was performed on the rats as follows.
  • 7-week-old SD rats were purchased from KOATECH, adapted for 1 week, and randomly divided into two groups, each group having 5 rats. First, 50 mg/kg of myricetin was administered into the test group, and phosphate buffered saline was administered into the control group for 5 days.
  • a change in body weight was measured using an electric balances (CAS, China). Before administration, the body weights of the rats in each group were the same as 225 g on average, but after the end of the experiment, the body weights of the rats in the control group were 285 g on average, and the body weights of the rats in the myricetin-administered group were 275 g on average ( FIG. 5A ). As a result, as shown in FIG. 5A , it was observed that the body weight of the myricetin-administered mouse was lower than that of the mouse to which the phosphate buffered saline was administered.
  • the investigation of food intake was performed by automatically measuring the daily food intake of the phosphate buffered saline-administered mouse and the myricetin-administered mouse using a metabolic cages (Panlab&Harvard, Spain).
  • the average food intake was determined as an average food intake of each of the five rats in one group.
  • FIG. 5B it was observed that the myricetin-administered mouse was smaller than that of the phosphate buffered saline-administered mouse.
  • a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient enhances exercise capacity and physical strength, prevents aging, enhances recovery from fatigue, improves the function of mitochondria to increase energy efficiency and energy consumption, and therefore also has an antiobesity effect. For this reason, the composition is expected to be significantly applied to a functional food or medicine field.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
US14/435,424 2012-10-11 2013-09-16 Composition comprising myricetin as active ingredient for enhancing exercise performance or fatigue recovery Abandoned US20150283112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020120113176A KR101454425B1 (ko) 2012-10-11 2012-10-11 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물
KR10-2012-0113176 2012-10-11
PCT/KR2013/008372 WO2014058160A1 (fr) 2012-10-11 2013-09-16 Composition comprenant de la myricétine en tant que composant actif pour améliorer les performances d'effort ou la récupération de la fatigue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/008372 A-371-Of-International WO2014058160A1 (fr) 2012-10-11 2013-09-16 Composition comprenant de la myricétine en tant que composant actif pour améliorer les performances d'effort ou la récupération de la fatigue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/058,065 Division US9675580B2 (en) 2012-10-11 2016-03-01 Method of treatment for enhancing exercise performance

Publications (1)

Publication Number Publication Date
US20150283112A1 true US20150283112A1 (en) 2015-10-08

Family

ID=50477590

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/435,424 Abandoned US20150283112A1 (en) 2012-10-11 2013-09-16 Composition comprising myricetin as active ingredient for enhancing exercise performance or fatigue recovery
US15/058,065 Active US9675580B2 (en) 2012-10-11 2016-03-01 Method of treatment for enhancing exercise performance

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/058,065 Active US9675580B2 (en) 2012-10-11 2016-03-01 Method of treatment for enhancing exercise performance

Country Status (6)

Country Link
US (2) US20150283112A1 (fr)
EP (1) EP2907517A4 (fr)
JP (1) JP6267715B2 (fr)
KR (1) KR101454425B1 (fr)
CN (1) CN104755089A (fr)
WO (1) WO2014058160A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118497157A (zh) * 2024-07-08 2024-08-16 聊城大学 一种茶树杨梅素合成酶CsMs、其编码基因及应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180117000A1 (en) * 2015-04-10 2018-05-03 Oryza Oil & Fat Chemical Co., Ltd. Energy metabolic activating agent for muscle cells
CN109219659B (zh) 2016-04-14 2022-09-09 贝尼泰克生物制药有限公司 用于治疗眼咽型肌营养不良(opmd)的试剂及其用途
WO2019043846A1 (fr) 2017-08-30 2019-03-07 大塚製薬株式会社 Composition contenant un analogue du kaempférol
CN107375267A (zh) * 2017-09-21 2017-11-24 上海华堇生物技术有限责任公司 杨梅素的药物用途
JP2019112364A (ja) * 2017-12-26 2019-07-11 花王株式会社 運動調節機能向上剤
WO2019207553A2 (fr) * 2018-04-27 2019-10-31 Joslin Diabetes Center, Inc. Méthodes et compositions associées à des lipokines pour le traitement de troubles métaboliques
JP6883364B1 (ja) * 2020-05-25 2021-06-09 株式会社東洋新薬 経口組成物、筋肉増強用組成物並びに抗肥満用組成物
WO2023136399A1 (fr) * 2022-01-11 2023-07-20 주식회사 닥터오레고닌 Composition pour la prévention et le traitement de l'obésité et de la sarcopénie, comprenant un extrait de rhododendron mucronulatum en tant que principe actif

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1128069A (ja) * 1997-07-10 1999-02-02 Kyowa Hakko Kogyo Co Ltd 栄養補給飲食品
JP4082823B2 (ja) * 1999-05-06 2008-04-30 日本メナード化粧品株式会社 光毒性抑制剤
JP2011105763A (ja) * 2000-06-21 2011-06-02 Kao Corp Ｐｐａｒ依存的遺伝子転写活性化剤
KR100407399B1 (ko) * 2000-08-22 2003-11-28 주식회사 뉴로넥스 세로토닌 ｎ-아세틸트란스퍼라제의 활성 억제제
KR100599496B1 (ko) 2001-04-23 2006-07-12 한국생명공학연구원 간염 예방 또는 치료용 약학적 조성물
KR100526164B1 (ko) 2005-04-12 2005-11-08 한국식품연구원 운동수행능력 증강용 조성물
KR100701272B1 (ko) 2005-11-25 2007-03-29 부경대학교 산학협력단 백발억제 및 흑모유발 촉진용 조성물
KR100692099B1 (ko) 2006-03-17 2007-03-12 (주)아모레퍼시픽 3β-히드록시스테로이드 디하이드로게네이즈 활성 억제용피부화장료 조성물
KR20080035378A (ko) * 2006-10-19 2008-04-23 (주)아모레퍼시픽 글루코오스-6-인산 탈수소 효소의 활성 억제용 조성물
US20120252887A1 (en) * 2007-03-19 2012-10-04 Atm Metabolics Lllp Composition and method for treating diabetes and metabolic disorders
CN101254186A (zh) * 2008-04-03 2008-09-03 沈阳药科大学 一种杨梅素的医药新用途
KR101121737B1 (ko) 2009-07-01 2012-03-23 한동대학교 산학협력단 한국산 겨우살이 추출물을 함유한 기능성 흑마늘 토마토 음료 조성물
KR101120996B1 (ko) 2009-10-09 2012-03-13 대동고려삼 주식회사 진세노사이드 Ｒｇ３ 및 Ｒｇ２를 포함하는 운동능력증진 및 피로회복 증진용 조성물
EP2615931A1 (fr) * 2010-09-17 2013-07-24 Stokely-Van Camp, Inc. Procédés de réduction de la concentration de lactate sanguin
JP2012171911A (ja) * 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
TWI401030B (zh) * 2011-02-25 2013-07-11 Scent Blaster Corp 楊梅乳酪烘焙食品及其製備方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118497157A (zh) * 2024-07-08 2024-08-16 聊城大学 一种茶树杨梅素合成酶CsMs、其编码基因及应用

Also Published As

Publication number Publication date
WO2014058160A1 (fr) 2014-04-17
EP2907517A4 (fr) 2016-04-06
JP6267715B2 (ja) 2018-01-24
KR101454425B1 (ko) 2014-11-03
KR20140048402A (ko) 2014-04-24
US9675580B2 (en) 2017-06-13
CN104755089A (zh) 2015-07-01
US20160175277A1 (en) 2016-06-23
EP2907517A1 (fr) 2015-08-19
JP2015535218A (ja) 2015-12-10

Similar Documents

Publication Publication Date Title
US9675580B2 (en) Method of treatment for enhancing exercise performance
JP6215379B2 (ja) 抗疲労剤
JP6796097B2 (ja) 食欲不振制御化合物の組成物および使用方法
EP1997496B1 (fr) Composition contenant de la riboflavin et des composés de la classe des sésamines
KR102239075B1 (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물
JP6157928B2 (ja) 肝臓への脂肪蓄積抑制剤
CN115867270A (zh) 烟酰胺腺嘌呤二核苷酸（nad）浓度上升剂
JPWO2020130146A1 (ja) 筋質向上剤
CN108635492A (zh) 一种防治鸽毛滴虫病的中药组合物及其制备方法与应用
JP6677775B2 (ja) 筋肉増強剤
JP7264169B2 (ja) 間欠的持久力向上剤または血中ｐＨ上昇剤
US20220023393A1 (en) Pharmaceutical composition for preventing or treating obesity or sarcopenia, containing if1 as active ingredient
US11576875B2 (en) Composition comprising ethyl vanillin as effective ingredient for exhibiting effect of muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or sarcopenia suppression
KR102361657B1 (ko) 14-디옥시-11,12-디디히드로안드로그라폴라이드 석시네이트를 유효성분으로 함유하는 듀센형 근이영양증을 포함한 유전성 근육질환의 예방 또는 치료용 조성물
DK3119385T3 (en) COMPOSITION COMPREHENSIVE CANNEL ALDE AND ZINC TO IMPROVE SINKING
KR102246627B1 (ko) Ｈｍｂａ를 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물
US20090298895A1 (en) Use of thioproline in body weight reduction treatments
CN110420209B (zh) 一种治疗糖尿病周围神经痛的药物组合物及其应用
US20240082219A1 (en) Methods for ameliorating and preventing age-related muscle degeneration
WO2018225618A1 (fr) Promoteur de métabolisme d'ammoniac
JP2016160216A (ja) 持久力向上作用又は抗疲労作用を発揮させる方法
AU2021398645A1 (en) Composition for improving muscle flexibility
JP2014051459A (ja) 脂質代謝促進剤
CN116059195A (zh) 用于提高运动表现或预防或缓解疲劳的组合物和方法
CN115778957A (zh) 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: POSTECH ACADEMY-INDUSTRY FOUNDATION, KOREA, REPUBL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, KYONG-TAI;CHOI, BO-HWA;JUNG, HOE-YUNE;AND OTHERS;SIGNING DATES FROM 20150409 TO 20150410;REEL/FRAME:035408/0675

AS Assignment

Owner name: BIOKOGEN CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POSTECH ACADEMY-INDUSTRY FOUNDATION;REEL/FRAME:036995/0153

Effective date: 20150921

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION